WuXi Biologics (Cayman)

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption (si apre in una nuova scheda)

  GlobeNewswire · 1 ott 2026

• 
  WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability (si apre in una nuova scheda)

  PR Newswire · 24 set 2026

• Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong (si apre in una nuova scheda)

  富途牛牛 · 24 set 2026

• 
  WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership (si apre in una nuova scheda)

  PR Newswire · 16 set 2026

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (si apre in una nuova scheda)

  14 set 2026

• 
  WuXi Biologics Reports Strong Profitable Growth in H1 2026 (si apre in una nuova scheda)

  PR Newswire · 25 ago 2026

• 
  WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO (si apre in una nuova scheda)

  PR Newswire · 18 ago 2026

• 
  Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition? (si apre in una nuova scheda)

  Simply Wall St. · 31 lug 2026

• 
  WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO (si apre in una nuova scheda)

  PR Newswire · 29 lug 2026

• 
  WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (si apre in una nuova scheda)

  PR Newswire · 9 lug 2026

• 
  WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year (si apre in una nuova scheda)

  PR Newswire · 8 lug 2026

• 
  WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy (si apre in una nuova scheda)

  PR Newswire · 30 giu 2026

• WuXi Biologics on target for 2028 opening in Worcester (si apre in una nuova scheda)

  29 giu 2026

• 
  WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations (si apre in una nuova scheda)

  PR Newswire · 24 giu 2026

• 
  WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards (si apre in una nuova scheda)

  PR Newswire · 8 giu 2026

• WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility (si apre in una nuova scheda)

  5 giu 2026

• WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year (si apre in una nuova scheda)

  3 giu 2026

• WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing (si apre in una nuova scheda)

  26 mag 2026

• WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index (si apre in una nuova scheda)

  13 mag 2026

• Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness (si apre in una nuova scheda)

  11 mag 2026